BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 32853178)

  • 1. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
    Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
    Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.
    Borgo C; D'Amore C; Capurro V; Tomati V; Sondo E; Cresta F; Castellani C; Pedemonte N; Salvi M
    Cell Mol Life Sci; 2022 Mar; 79(4):192. PubMed ID: 35292885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.
    Becq F; Mirval S; Carrez T; Lévêque M; Billet A; Coraux C; Sage E; Cantereau A
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34266939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.
    Laselva O; Bartlett C; Gunawardena TNA; Ouyang H; Eckford PDW; Moraes TJ; Bear CE; Gonska T
    Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33303536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
    Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
    Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment.
    Shaughnessy CA; Zeitlin PL; Bratcher PE
    Sci Rep; 2021 Oct; 11(1):19810. PubMed ID: 34615919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors.
    Saint-Criq V; Wang Y; Delpiano L; Lin J; Sheppard DN; Gray MA
    J Cyst Fibros; 2021 Sep; 20(5):843-850. PubMed ID: 34020896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR.
    Veit G; Vaccarin C; Lukacs GL
    J Cyst Fibros; 2021 Sep; 20(5):895-898. PubMed ID: 33775603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta.
    Liessi N; Pesce E; Braccia C; Bertozzi SM; Giraudo A; Bandiera T; Pedemonte N; Armirotti A
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32673287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
    Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
    Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
    Hoy SM
    Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro.
    Shaughnessy CA; Zeitlin PL; Bratcher PE
    J Cyst Fibros; 2022 Jul; 21(4):637-643. PubMed ID: 35248469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR.
    Baatallah N; Elbahnsi A; Mornon JP; Chevalier B; Pranke I; Servel N; Zelli R; Décout JL; Edelman A; Sermet-Gaudelus I; Callebaut I; Hinzpeter A
    Cell Mol Life Sci; 2021 Dec; 78(23):7813-7829. PubMed ID: 34714360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
    Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
    Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.